AEGiS-WSJ: Collaborative Research Buys Rights to Develop Genetic Disease Test Wall Street JournalImportant note: Information in this article was accurate in 1984. The state of the art may have changed since the publication date.
Click here to return to Wall Street Journal main menu




DonateNow



Collaborative Research Buys Rights to Develop Genetic Disease Test

The Wall Street Journal - 29 February 1984.


NEW YORK -- Collaborative Research Inc. said it acquired exclusive rights under a license from Stanford University to develop a method of diagnostic testing for genetic diseases.

The research project will use recently invented DNA probe technology to identify inherited disease characteristics on human chromosomes, Collaborative Research said.

The Lexington, Mass.-based biotechnology company said the technology would be marketed through a joint venture with American Hospital Supply Corp.

Collaborative Research said it was exploring the formation of a research and development partnership to fund the project.

The company also said it will expand clinical trials of its Interleukin-2 product. Interleukin-2 is used to improve the functioning of the immune systems of patients with acquired immune deficiency syndrome, or AIDS.

Collaborative Research said it signed an agreement in principle with Triton Biosciences Inc., a subsidiary of Shell Oil Co., to underwrite clinical trials of Interleukin-2.

Under the agreement, Triton initially has a 45-day option to fund the clinical trials. With the exercise of its option,

Triton would have exclusive world-wide marketing and distribution rights for the drug, when regulatory approval is obtained.

Separately, Collaborative Research said it signed a world-wide licensing agreement with Corning Glass Works, Corning, N. Y., to market Collaborative Research's medical diagnostic technology. Terms of the agreement weren't disclosed.

The company said the technology can be used to test for pregnancy, syphilis, hepatitis and cancer. It also can be used to identify cancer causing agents and toxins in food and in the environment, the company said.
840229
WJ840202


Copyright © 1984 - The Wall Street Journal. Reproduction of this article (other than one copy for personal reference) must be cleared through the WSJ Permissions Desk.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1984. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1984. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .